Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations

2y
2m read
Summary

EU GMP medical cannabis products can be sold worldwide anywhere medical cannabis is legal. Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S) Under the DKMA licensing, Valcon Medical is authorized to produce medical cannabis in accordance with section 9(1) of the Act on the Medicinal Cannabis Pilot Programme. Valcon Medical will be providing broad-spectrum concentrates, and extracted medical cannabis isolates, as well as bespoke formulations and active pharmaceutical ingredients (API) to the global legal cannabis industry. About Valcon Medical Founded in 2018, Valcon Medical is a medical cannabis product manufacturing organization based in Denmark. COPENHAGEN, June 22, 2021 /PRNewswire/ — Valcon Medical A/S (“Valcon Medical” or the “Company”), Denmark’s leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021.

Article Preview

COPENHAGEN, June 22, 2021 /PRNewswire/ — Valcon Medical A/S (“Valcon Medical” or the “Company”), Denmark’s leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021.

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start...

Read the full article @ Cannabis Law Report